July 23, 2020 via NextBigTicker.com

PAO Group, Inc. (USOTC: PAOG) announced a management takeover and medical cannabis strategy revitalization last week that sent the stock soaring nearly 1000% from $0.0003 to $0.003.  The next step in PAOG’s revitalization strategy has the potential to send the PPS to as high as $0.10.

The revitalization involves two pending acquisitions.   One of the acquisitions will give PAOG a treatment for Chronic Obstructive Pulmonary Disease (COPD) derived from a U.S. patented cannabis extraction process.  The developing drug is called RespRx and the market for COPD treatment is anticipated to reach $14 billion by 2025.

The PAOG PPS has already broken through its 50 Day and 200 Day Moving Averages (MA).  The 50 Day MA Price has now crossed above 200 Day MA attracting technical bulls that also enjoy the massive trading volume. 

The PAOG PPS was over $0.01 in January of 2019 and little is standing in the way of the PPS rapidly returning to the $0.01 level.

The company has indicated both acquisitions are expected to be closed by the end of July.  That’s next week.  An announcement of the RespRx acquisition could trigger a run.

A $100 million valuation is not exceptional in a market where pre-money valuations of biotechs easily exceeds $100 million.  OTC trading dynamics might lend to resistance of the PAOG stock climbing to a $0.10 PPS and $100 million valuation, but then again, those same OTC trading dynamics could lend support.

With the PAOG PPS having already exceeded the $0.01 level in recent history with less resources and assets under the hood, a PAOG breakthrough over a penny is a strong possibility.

GW Pharmaceuticals (GWPH) has blazed the trail for cannabis pharmaceuticals.  Frederick Ferri, CEO of PAOG’s target medical cannabis acquisition said, "Doctors involved in research with our extracts have given me feedback that our extracts are superior to those of GW Pharmaceuticals.”

PAOG’s target medical cannabis acquisition, in collaboration with Beech Tree Labs, Inc. (BTL) conducted a series of in vitro genomic experiments to evaluate the potential of the target’s cannabis extracts derived from the subject patented extraction process in the treatment of respiratory diseases.  There are a significant number of genes associated with COPD and Asthma.  The experiments evaluated the ability of various formulations to change Asthma or COPD associated gene expressions in human small airway epithelial cells.  A cannabis extract alone demonstrated remarkable activity in gene arrays by up- or down-regulating individual genes by as much as 200-fold.  Genes appearing especially sensitive to the introduction of cannabis extract were associated with inflammation, healing and cancer inhibition.  

According to the World Health Organization, 65 million people have moderate to severe COPD with three million deaths annually. The treatment of COPD is currently estimated to be $5 billion in the United States and $11 billion worldwide.


NextBigTicker.com (NBT) is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.NextBigTicker.com

GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more GW Pharmaceuticals Charts.
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more GW Pharmaceuticals Charts.